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Abstract
Background: Aberrant hypermethylation of CpG islands in housekeeping gene promoters and widespread genome
hypomethylation are typical events occurring in cancer cells. The molecular mechanisms behind these cancer-related
changes in DNA methylation patterns are not well understood. Two questions are particularly important: (i) how are CpG
islands protected from methylation in normal cells, and how is this protection compromised in cancer cells, and (ii) how
does the genome-wide demethylation in cancer cells occur. The latter question is especially intriguing since so far no DNA
demethylase enzyme has been found.
Methodology/Principal Findings: Our data show that the absence of ADP-ribose polymers (PARs), caused by ectopic over-
expression of poly(ADP-ribose) glycohydrolase (PARG) in L929 mouse fibroblast cells leads to aberrant methylation of the
CpG island in the promoter of the Dnmt1 gene, which in turn shuts down its transcription. The transcriptional silencing of
Dnmt1 may be responsible for the widespread passive hypomethylation of genomic DNA which we detect on the example
of pericentromeric repeat sequences. Chromatin immunoprecipitation results show that in normal cells the Dnmt1 promoter
is occupied by poly(ADP-ribosyl)ated Parp1, suggesting that PARylated Parp1 plays a role in protecting the promoter from
methylation.
Conclusions/Significance: In conclusion, the genome methylation pattern following PARG over-expression mirrors the
pattern characteristic of cancer cells, supporting our idea that the right balance between Parp/Parg activities maintains the
DNA methylation patterns in normal cells. The finding that in normal cells Parp1 and ADP-ribose polymers localize on the
Dnmt1 promoter raises the possibility that PARylated Parp1 marks those sequences in the genome that must remain
unmethylated and protects them from methylation, thus playing a role in the epigenetic regulation of gene expression.
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Introduction
5-methylcytosine is considered to be the fifth base of DNA as –
through its non-random distribution along the genome – it
constitutes part of the epigenetic chromatin modifications that
control gene expression patterns. The genome methylation pattern
is bimodal: the methylated cytosines are scattered throughout the
genome, whereas the unmethylated residues are mainly located
within particular regions termed CpG islands (CGIs) [1–3]. The
37,000 CGIs in the mouse genome represent 1–2% of the DNA
and are generally located in the 59 promoter regions of the
housekeeping genes, sometimes overlapping the coding region to
variable extents. Although their sequence is enriched in CpG
dinucleotides, the best substrates for DNA methyltransferase
activity, the CGIs are mainly unmethylated and the associated
genes are actively transcribed; transcription is inhibited when these
regions undergo methylation [4–7].
In cancer cells, there are drastic changes in the DNA
methylation patterns: the housekeeping gene promoters become
hypermethylated, whereas the genome as a whole undergoes
significant hypomethylation events. The mechanisms by which
CGIs are protected from methylation in both replicating and non-
replicating chromatin in normal cells, and the mechanism(s)
whereby these DNA regions become susceptible to methylation
in tumor cells are still unknown [2,8,9]. The inversion of DNA
methylation patterns observed on inactive X vs active X
chromosomes is also far from understood [2].
A significant amount of research has been carried out over the
years to see if the levels of Dnmt1 control the aberrant methylation
pattern in tumor cells and in cells where Dnmt1 was stably
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4717overexpressed [10,11]. Indeed, Dnmt1 silencing allows demethyl-
ation and re-expression of some germ-line specific genes whose
repression is methylation-dependent in somatic cells [12,13]. The
promoters of these genes become demethylated also in many
tumor cells, opening up the possibility that passive demethylation,
due to silencing of Dnmt1, is involved in determining the diffuse
genome-wide hypomethylation which has been associated with
chromatin decondensation [8], genomic instability [14], apoptosis
[15], cancer [4,6,7,16], disruption of nucleolar architecture [17],
aberrant telomere elongation [18], loss of imprinting during
preimplantation development [19,20], and even mitotic catastro-
phe [21].
Over the past decade our laboratory has accumulated evidence
that links poly(ADP-ribosyl)ation with DNA methylation, suggest-
ing that poly(ADP-ribosyl)ation is involved in maintaining DNA
methylation patterns. A series of different experimental strategies
suggests that blockage of poly(ADP-ribosyl)ation, due to compet-
itive inhibition of poly(ADP-ribose) polymerases (PARPs), induces
in vivo DNA hypermethylation, both on genomic DNA [22–24]
and on particular CGI regions [25]. On the other hand, cells with
hyperactive Parp1 are characterized by a widespread DNA
hypomethylation [26]. We have suggested a mechanism in which
Parp1 in its automodified (PARylated) form or PARs themselves
make Dnmt1 catalytically inactive and, thus, inefficient in DNA
methylation [27]. In this model, modified Parp1, through the high
negative charge of bound PARs attracts and hosts Dnmt1, thus
preventing its catalytic activity. In fact, we found that Dnmt1
possesses two presumptive PAR-binding domains and shows
higher affinity for free polymers than for DNA. Co-immunopre-
cipitation data indicated that Dnmt1 and Parp1 associate in vivo
and that the Parp1 present in the complex is in its PARylated form
[27].
We hypothesize that the right nuclear balance between
unmodified and PARylated forms of Parp1 – which depends on
the correct dynamics of Parp/Parg activities – determines the
maintenance of DNA methylation patterns [28]. According to our
data, decreased or increased levels of PARylated Parp1 are
responsible for diffuse hypermethylation or hypomethylation of
DNA, respectively. In the absence of PARylated Parp1, Dnmt1 is
free to methylate DNA; conversely, under conditions of persis-
tently high levels of PARylated Parp1, the stable inhibition of
Dnmt1 would prevent its methylation-maintenance activity at
replicative forks, thus leading to passive DNA hypomethylation of
the genome.
These findings underscore the importance of a rapid reversal of
Parp1 automodification since it affects the epigenetic information.
They also suggest that the introduction of new methyl groups onto
CGIs of housekeeping genes and/or the diffuse genome
hypomethylation in cancer cells could also occur through
deregulation of Parp or Parg activities.
In this work, the non-specific effects of inhibitors of Parp activity
were excluded by using ectopic over-expression of PARG to
deplete cells of PARs. We show that following over-expression of
PARG: i) Dnmt1 expression is down-regulated; ii) the CGI in the
promoter of Dnmt1 loses its protection against methylation and
becomes methylated; iii) in normal cells, Parp1 and PARs locate
on the Dnmt1 minimal promoter; iv) the silencing of the Dnmt1
gene is accompanied by diffuse demethylation of the genome,
including the pericentromeric repeat sequences which are
methylated in normal cells. These findings suggest that Parp1
occupies the Dnmt1 promoter and protects its unmethylated state
through its automodification activity, i.e. its ability to build
poly(ADP-ribose) chains onto itself.
Results
Myc-PARG localizes in the nucleus of transfected L929
mouse fibroblasts and degrades endogenous PARs
The complete coding region for human PARG was cloned into
the Myc-tag expression vector pCS2-MT and the expression of the
Myc-PARG protein was evaluated in transfection assays in the
mouse fibroblast cell line L929.
Figure 1A shows a predominant nuclear localization of Myc-
PARG at 48 hours of transient transfection, as evaluated by
immunofluorescence analysis. Western blot experiments per-
formed on nuclear lysates of over-expressing cells show that the
level of Myc-PARG, (which is stable up to 72 hours of puromycin
selection, Figure 1 B, middle panel), introduces a sharp decrease in
PARs, when compared to PARs level either in non-transfected
cells or in cells transfected with empty vector (Figure 1B, upper
panel). These results clearly demonstrate the capability of Myc-
PARG to act on endogenous substrates, causing an almost
complete disappearance of PARs.
With the aim of evaluating the effect of Myc-PARG over-
expression on cell viability, we measured the percentage of live
cells by the trypan blue-exclusion assay at 24 and 72 hours of
puromycin selection. Although we observed a significant reduction
in the number of live cells within each sample between 24 and
72 hours of selection, the survival level in the Myc-PARG over-
expressing cultures was not affected (if anything, it slightly
increased in comparison with the control cultures) (Figure S1 A).
The evaluation of lactate dehydrogenase (LDH) activity in the
Figure 1. Ectopic over-expression of PARG. A, Immunofluores-
cence images showing the nuclear localization of ectopically over-
expressed PARG. B, Western blot of proteins from cell cultures at 24 and
72 hours of puromycin selection (p.s.) transfected with pCS2-Myc-PARG
vector 24 hours before selection vs control cells. Analyses were
performed using anti-PAR antibodies, anti-Myc epitope antibody for
Myc-PARG; anti-Sp1 antibody was used as endogenous control. pCS2:
empty vector; pCS2-Myc-PARG: vector containing full length cDNA for
human PARG.
doi:10.1371/journal.pone.0004717.g001
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the cytotoxicity depended on the transfection procedure, and not
on the Myc-PARG over-expression (Figure S1 B). Methods used
for determination of cell viability, cell-cycle progression and
cytotoxicity are available as supporting information (Materials and
Methods S1).
Dnmt1 expression is down-regulated in Myc-PARG over-
expressing L929 cells
Western blot experiments (Figure 2A) carried out on nuclear
lysates show that the Dnmt1 protein level decreases after Myc-
PARG over-expression. Real-time RT-PCR experiments show
that this reduction depends on down-regulation of Dnmt1 mRNA
level (Figure 2B), suggesting a regulatory role of PAR in Dnmt1
gene transcription.
As the expression level of Dnmt1 is cell-cycle dependent, we
checked the cell cycle progression by FACS analysis. We excluded
any cytostatic effect of Myc-PARG over-expression under the
adopted experimental conditions, as we did not detect significant
differences between samples except for the sub-G1 fraction, which
could be due to puromycin selection (Figure S2).
Myc-PARG-mediated PAR depletion disrupts the
methylation pattern of the CGI located in 59 regulatory
region of Dnmt1
Based on our previous data demonstrating the introduction of
anomalous methyl groups onto some CGIs upon competitive
inhibition of Parp activity [25], we hypothesized that the down-
regulation of Dnmt1 gene expression observed in PARG over-
expressing cells is associated with changes in the methylation
pattern of its promoter. By bisulphite sequencing we determined
the methylation pattern of a portion of the CpG island in the
Dnmt1 promoter region in close proximity to the transcription start
site (Figure 3A). Methylation pattern analysis was performed on
15–20 clones for each sample. The twelve CpG dinucleotides,
present in the sequence under examination, were found methyl-
ated in ,30% of the clones at 24 hours of puromycin selection
(48 hours from transfection), with ,55% of the clones methylated
at 72 hours of puromycin selection (96 hours from transfection).
These 12 CpG dinucleotides are unmethylated in the control
sample (Figure 3B). The increased percentage of methylated clones
may reflect the increased clearing of untransfected cells by
puromycin at the longest selection time (Figure S1A).
PARs and Parp1 localize at the Dnmt1 minimal promoter
Chromatin immunoprecipitation (ChIP) experiments were
performed to verify if PARs and Parp1 colocalize on the Dnmt1
promoter to prevent its methylation in normal cells. Cross-linked
chromatin was immunoprecipitated with antibodies anti-PARs and
anti-Parp1. The region of DNA of about 1000 bp – covering the
proximal promoter region (amplicons D1–D4) or the distal region
(D5) – was probed and the presence of each fragment was evaluated
by quantitative PCR (Figure 4A). Primers specific for the b-actin
promoter were used as control. ChIP analysis, carried out with anti-
PAR antibodies, showed that PARs are particularly enriched within
the region spanning from 231 to 2292 bp (primers D1 and D2),
overlapping the Dnmt1 minimal promoter located within 300 bp
from the first codon [29]. Conversely, the more distal regions did
not show any enrichment in PARs when compared with the control
b-actin promoter (Figure 4B). As it is well known that Parp1 is
responsible for more than 90% of PAR synthesis in cells, we
performed ChIP analysis with antibodies against Parp1 to assess
whether Parp1 could harbour PARs at the Dnmt1 promoter.
Figure 4C shows that Parp1 specifically localizes within the region
amplified by D1 primers, which was found to be also highly
enriched in PARs. Significant positive signals were not detected for
the other Dnmt1 promoter regions under consideration or for the b-
actin promoter control. Immunoprecipitation experiments, carried
out with both anti-Parp1 and anti-Dnmt1 antibodies, confirmed
earlier results [26,27] that the two proteins interact in vivo and that
Parp1 is PARylated in the complex (Figure 4D).
Our attention was then focused on the highly conserved and
ubiquitously expressed nuclear factor Ctcf [30], as this protein, whichis
one of the major players in imprinting and insulator processes [31,32],
puts together the two epigenetic events we are interested in: poly(ADP-
ribosyl)ation [33,34] and DNA methylation [35–37]. Thousands of
Ctcf binding sites have been identified in recent genome-wide
localization studies, and their distribution along the genome further
supports a crucial role of Ctcf as a chromatin organizer [38–41].
Our previous data showed that Parp1 becomes PARylated
when it interacts with Ctcf, i.e. Ctcf activates Parp1 [26].
Therefore, Ctcf is an important player in the Parp1/Dnmt1
interplay since PARylated Parp1 plays an inhibitory role on
Dnmt1 activity [26]. ChIP assays with antibodies against Ctcf
were performed to verify if Ctcf interacting with Parp1 is
Figure 2. Ectopic over-expression of PARG leads to down-
regulation of Dnmt1 expression. A, Nuclear lysates from cultures
transfected with pCS2 and pCS2-Myc-PARG vectors at 24 and 72 hours
of puromycin selection were analyzed by SDS-PAGE and Western blot
using anti-Myc epitope and anti-Dnmt1 antibodies; anti-Sp1 antibodies
served as endogenous control. B, Real time RT-PCR for Dnmt1
performed on RNA samples from cell cultures transfected with pCS2
and pCS2-Myc-PARG vectors at 24 and 72 hours of puromycin selection.
Gapdh (white bar) and Hprt1 (black bar) mRNAs were used as
endogenous controls. Data are reported as mean6S.E. of the ratio of
Dnmt1 mRNA level to Gapdh or Hprt1 mRNA level within each sample,
calculated from a minimum of three experiments performed in
duplicate.
doi:10.1371/journal.pone.0004717.g002
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promoter. The data presented in Figure 5A indicate that Ctcf was
not present on the Dnmt1 promoter. The involvement of Ctcf in
the maintaining of the unmethylated state of Dnmt1 promoter was
further disproved by Ctcf siRNA-silencing assays where Dnmt1
expression was not affected by a decreased level of Ctcf (Figure 5B).
Myc-PARG over-expression affects the DNA methylation
machinery
The down-regulation of Dnmt1 expression occurring as a result
of Myc-PARG mediated PAR degradation prompted us to look
for effects on the DNA methylation machinery and the genome-
wide methylation patterns. The ability of nuclear lysates to
methylate exogenous DNA is gradually compromised after
transfection of Myc-PARG (Figure 6A). These data correlate with
results of DNA methyl-accepting ability assays showing a
widespread hypomethylation of DNA extracted from cells over-
expressing PARG (Figures 6B). The enhanced incorporation of
exogenous labelled methyl groups on this DNA vs the respective
controls reveals that the genome underwent demethylation (the
demethylated DNA has higher DNA methyl-accepting ability).
Analyses of the methylation state of methyl-CpG rich centromeric
Figure 3. Ectopic over-expression of PARG changes the methylation pattern of the CGI located in 59 regulatory region of the Dnmt1
gene. A, Graphical representation of the CGI region (gray line) in the promoter region of Dnmt1. Numbers indicate the distance in base pairs from the
first codon (black arrow); TSS: transcription start site; dashes: GpG dinucleotides. B, The methylation state of Dnmt1 promoter region spanning base
pairs 2364 to 2103 was evaluated by bisulphite sequencing following transfection with either pCS2 or pCS2-Myc-PARG vectors at 24 and 72 hours of
puromycin selection. Up to twenty independent clones for each sample were analysed by the sequencing procedure. Each row of circles represents
the sequence of an individual clone. Open circle, unmethylated CpG site; filled circle, methylated site. Frequency: number of clones with depicted
methylation pattern of all clones tested under the specified conditions.
doi:10.1371/journal.pone.0004717.g003
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restriction enzyme HpaII, show that new unmethylated cutting-
prone sites are formed in these sequences when Myc-PARG is
overexpressed, resulting in enhanced fragmentation (Figure 6C).
Discussion
The data reported here indicate that, following ectopic over-
expression of PARG, the promoter of Dnmt1 is no longer protected
from anomalous methylation; moreover, the insertion of new
methyl groups onto the CpG island in the promoter region leads to
transcriptional down-regulation of the gene. We have earlier
shown that PARs - either protein free or bound to PARylated
Parp1 - compete with DNA for binding to Dnmt1; when the
enzyme is hosted on the polymers, it can no longer perform its
catalytic function on DNA [27]. Here, we suggest that the CGI in
the promoter of Dnmt1 is protected from methylation by
PARylated Parp1 or a PARylated transcriptional factor which
Figure 4. ChIP analysis of Dnmt1 promoter occupancy by PARs and Parp1. A, Schematic representation of the Dnmt1 promoter region with
approximate locations of the amplicons used to detect the presence of Dnmt1 sequences in ChIP complexes. ChIPs were carried out with anti-PAR (B)
and anti-Parp1 (C) antibodies. Controls were non-specific normal rabbit IgGs (IgG) or no antibody (No Ab). DNA was amplified by real-time PCR with
primer sets for the amplicons indicated in A; a primer set for the b-actin promoter was used as control. Numbers refer to distance in base pairs from
the first codon. Data are expressed as percentage of the signal detected for the non-immunoprecipitated input (4% of the chromatin subjected to
immunoprecipitation) taken as 100%. D, Western Blot analysis of samples immunoprecipitated with either anti-Parp1 or anti-Dnmt1 antibodies; anti-
PAR antibody was used to detect polymers in the immunoprecipitated complexes.
doi:10.1371/journal.pone.0004717.g004
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precipitation experiments using anti-PAR and anti-Parp1 anti-
bodies, we showed that the Dnmt1 promoter region that was
methylated following PARG over-expression, contained both
Parp1 and PARs in control (non-over-expressing) cells. We can
conclude that in normal cells PARylated Parp1 (or a PARylated
transcription factor) occupies the Dnmt1 promoter, maintaining
this region unmethylated.
To establish whether PARylated Parp1 by itself can regulate the
promoter region of Dnmt1 gene, we focused our attention on the
transcriptional factor Ctcf. We excluded the involvement of Ctcf in
this mechanism as: (i) the Dnmt1 promoter could not be chromatin
immunoprecipitated with anti-Ctcf antibody, and (ii) decreased
levels of Ctcf did not affect the level of Dnmt1. We cannot exclude
that Parp1 is recruited to the Dnmt1 promoter by other
transcription factors. The predictive Transfac search for tran-
scription factor binding sites within the promoter region amplified
by D1 and D2 primers revealed multiple putative binding sites for
transcription factors, some of which are known to interact with
Parp1. In particular, the promoter region from 231 bp to 264 bp
from the first codon, which is specifically amplified by D1 primers,
contains predicted binding sites for p300, SRY, and E2F
transcription factors, recognized Parp1 partners [42–44].
In the absence of PARs, the molecular mechanism that protects
the unmethylated state of the Dnmt1 promoter is lost, with
consequent introduction of new methyl groups onto the promoter
CpGs, and silencing of the gene. As Dnmt1 is one of the most
important players in maintaining the genome methylation pattern
during DNA replication, the silencing of the gene in turn leads to
widespread passive hypomethylation.
In conclusion, the deregulation of PAR levels, dependent on the
balance between PARP and PARG activities, may lead to reversal
of the normal methylation pattern by (i) introducing aberrant
methylation of some normally unmethylated CGIs (e.g. Dnmt1 CGI)
and (ii) causing genome-wide hypomethylation. The changes in the
DNAmethylationpatterns causedbyover-expressingPARG, i.e.by
persistently low levels of polymers, mimic the epigenetic changes
that occur in cancer, where there is hypermethylation of the CGI
promoter regions of tumor suppressor genes and widespread
genomic DNA hypomethylation [45].
Experiments with PARG over-expression reveal an additional
mechanism responsible for the widespread genomic hypomethyla-
tion in cancer cells. In the previously established mechanism high
levels of PARylated PARP-1 inhibit Dnmt1 activity by hosting the
enzyme on the poly(ADP-ribose) polymers [26]. The new
mechanism, on the other hand, functions under conditions of
polymer levels too low to inhibit Dnmt1 activity; in these conditions,
new methyl groups are inserted onto the Dnmt1 promoter, which
leads to down-regulation of the gene. Thus, poly(ADP) ribose
levels that are either too high or too low lead to the same outcome
in terms of the global methylation status of the genome: they both
cause widespread genome hypomethylation. These results under-
score once again the critical importance of keeping balanced
polymer levels, as we have recently argued [28].
Recently, Parp has been implicated in multiple pathways that
regulate gene expression, including effects on chromatin structure
[46,47] and transcriptional activator and coactivator functions
[48]. Our findings add another dimension to the regulatory
functions of Parp, through affecting DNA methylation patterns. A
new question now emerges: does PARylated Parp1 introduce an
epigenetic mark on chromatin? PARylated Parp1 could mark
those DNA sequences that must be maintained in a non-
methylated state in normal cells and directly prevent Dnmt1
access to these sequences.
Materials and Methods
Cell culture and drug treatment of cells
L929 mouse fibroblasts were maintained as sub-confluent
culture in high glucose (4.5 g/litre) Dulbecco’s modified Eagle’s
medium, supplemented with 10% fetal calf serum, 2 mM L-
glutamine, 50 units/ml Penicillin and 50 mg/ml Streptomycin. All
culture solutions were from International PBI.
To obtain hypomethylated DNA, cells were cultivated for
72 hours in standard medium containing 5 mM 5-azacytidine (5-
AZA) (Sigma).
Plasmids construction and transfection of cells
Human PARG cDNA, containing the complete coding region,
was isolated by PCR amplification using as template cDNA
prepared from poly A+ selected RNA from human adult skeletal
muscle. The following oligonucleotides were used in the PCR
reaction: 59-CCGGAATTCAATGAATGCGGGCCCCGGC-
TGTGAACCC-39 sense, -59-GCCGCTC GAGTCAGGTCC-
CTGTCCTTTGCCCTGAATG-39 antisense. The amplified
DNA fragment was cloned in the Myc-tag expression vector
pCS2-MT and sequenced by GeneLab Service (Enea-Casaccia).
Figure 5. ChIP analysis of Dnmt1 promoter occupancy by Ctcf.
A, ChIP was carried out with anti-Ctcf antibodies. The imprinting control
region ICR M4 (Igf2/H19 locus) was used as a positive control for Ctcf
binding (For further specifications about control ChIPs and the set of
primers used see legend to figure 4). B, Western Blot analysis of total
cell lysates from L929 cells transfected with anti-Ctcf siRNA and
detected with anti-Ctcf and anti-Dnmt1 antibodies. b-Actin served as
endogenous control.
doi:10.1371/journal.pone.0004717.g005
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6 cells were seeded in
60615 mm culture dishes (Greiner bio-one) and transfected with
Lipofectamine Plus reagent (Invitrogen) adopting the manufactur-
er’s protocol. Assays were performed with 4 mg/dish of purified
plasmid DNA of either empty myc-vector (pCS2) as control or
Myc–PARG construct (pCS2-Myc-PARG) together with 0.4 mg/
dish of pBabe-puro (Addgene) vector for puromycin selection of
transfected cells. After 24 hours cells were incubated for further 24
or 72 hours in culture medium supplemented with puromycin
(2 mg/ml, Calbiochem). Apart from seeding 0.25610
6 cells/dish
and omitting pBabe-puro and puromycin selection, the same
procedure was employed in transient transfection assays.
Western blot analysis
Nuclei were collected from trypsinized and phosphate-buffered
saline (PBS)-washed cells by centrifugation following incubation
(30 minutes) in isolation buffer containing 10 mM Tris-HCl
pH 7.9, 4 mM MgCl2, 1 mM EDTA, 0.5 mM dithiothreitol,
0.25 mM sucrose, 1% Triton X-100. Nuclear fraction was lysed in
RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 0.5%
sodium deoxycholate, 0.1% SDS, 1% Nonidet P-40, 1 mM
EDTA). Both buffers were supplemented with protease inhibitors
(complete EDTA-free, Roche Applied Science). Protein concen-
tration was determined using the Bradford protein assay reagent
(Bio-Rad) with bovine serum albumin (Promega) as standard.
Equal protein amounts were subjected to 8% SDS-PAGE and
blotted onto Hybond-ECL nitrocellulose membranes (Amersham
Biosciences). The antibodies employed were as follows: mouse
monoclonal Ab anti-PAR (10 HA, Trevigen), mouse monoclonal
Ab anti-Myc (9E10 clone, hybridoma-conditioned medium),
mouse monoclonal Ab anti-Dnmt1 (Imgenex), mouse monoclonal
Ab anti-b-Actin (Sigma), mouse monoclonal Ab anti-Parp1 (C2-
10, Alexis), rabbit polyclonal Ab anti-Ctcf (Upstate), rabbit
polyclonal Ab anti-Sp1 (H-225, Santa Cruz Biotechnology), and
goat antimouse and anti-rabbit horseradish peroxidase-conjugated
antibodies (Santa Cruz Biotechnology).
Immunofluorescence
Immunofluorescence was performed to detect Myc-PARG.
Transiently transfected L929 cells (at 48 hours following transfec-
tion) were fixed and permeabilized in methanol/acetone mixture
3:7, for 20 min at RT and then incubated for 1 hour with anti-
myc hybridoma conditioned medium (9E10). Bound antibody was
visualized using Alexa Fluor-rhodamine-conjugated anti-mouse Ig
Figure 6. Dnmt1 down-regulation dependent on PARG over-expression leads to a widespread genome hypomethylation. A,
Endogenous DNA methyltransferase activity (dnmt) of nuclear extract from cultures at 24 and 72 hours of puromycin selection transfected with either
pCS2 (white bar) or pCS2-Myc-PARG (black bar) vectors. The DNA methyltransferase activity of pCS2 samples was considered as 1.0. B, Methyl-
accepting ability assay was carried out on genomic DNA purified from cells transfected with either pCS2 (white bars) or pCS2-Myc-PARG (black bars)
vectors at 24 and 72 hours of puromycin selection. Results are displayed as number of picomoles of labelled S-Adenosyl methionine incorporated per
microgram of DNA. DNA obtained from cells treated with 5-AZA was used as positive control for genome hypomethylation (black bar). Data reported
in A and B are mean6S.E. of three experiments, each performed in triplicate. C, Analysis of Southern blot against minor satellite DNA repeats
performed on genomic DNA purified from cells transfected with either pCS2 or pCS2-Myc-PARG vectors at 24 and 72 hours of puromycin selection
and digested with HpaII or MspI restriction enzymes. DNA obtained from cells treated with 5-AZA was used as positive control for genome
hypomethylation.
doi:10.1371/journal.pone.0004717.g006
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staining with Hoechst (1 mg ml
21) (Sigma). Stained samples were
examined by conventional epifluorescence microscopy (Olympus
BX51; Tokio, Japan).
Extraction of nucleic acids
Plasmid DNA and genomic DNA were prepared by Plasmid
Maxi Kit and DNeasy tissue kit respectively (Qiagen). Total RNA
was purified by RNeasy mini kit (Qiagen). Concentration, purity
and integrity of preparations were evaluated spectrophotometri-
cally, followed by agarose gel-ethidium bromide electrophoresis.
qRT-PCR
Total RNA (1 mg) was subjected to retrotrascription using
Superscript First-Strand Synthesis system (Invitrogen). Expression
of mRNA for Dnmt1 was measured by real time PCR using Taq-
Man gene expression assays (Applied Biosystems) following the
manufacturer’s protocol for the absolute standard curve method
on iCycler IQ detection system (Bio-Rad). The standard curve was
generated using 1:1 serial dilutions (from 100 to 12.5 ng) of cDNA
obtained from control cells at 24 hours as reference. PCR
efficiency was 90–100% for each set of primers and probe in
any experiment. The amplification reaction was performed in
duplicate for each sample in 96-well plates. The amount of Dnmt1
mRNA was calculated adopting the standard curve method, and
normalization was carried out using hypoxanthine-guanine
phosphoribosyltransferase (Hprt1) and glyceraldehyde-3-phosphate
dehydrogenase (Gapdh) as internal control genes. TaqMan gene
expression assay IDs for each set of primers and probe were as
follows: Mm00599763m1 (Dnmt1); Mm00446968m1 (Hprt1) and
Mm99999915g1 (Gapdh).
Chromatin immunoprecipitation (ChIP)
Subconfluent L929 cell cultures (about 1610
5 cells/cm
2 in
standard culture dishes) were crosslinked at room temperature for
15 min by 1% formaldehyde (Fluka) in normal medium. Reaction
was stopped by 5 min incubation in 0.125 M Glycine (Sigma) in
PBS. Cell monolayer was harvested by scraping in ice-cold PBS
containing protease inhibitors. Cell lysis was performed in 1%
SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.0, protease
inhibitors. Soluble fraction from 10
6 cells was isolated by
centrifugation at 13.0006g for 15 min at 4uC. Lysate – 100 ml
per assay - was pre-cleared by addition of 0.9 ml of dilution buffer
(0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-
HCl pH 8.0, 167 mM NaCl, protease inhibitors) and 45 mlo f
protein A–Sepharose pre-blocked with salmon sperm DNA
(Upstate). A 40 ml aliquot corresponding to 4% of precleared
lysate was taken as input control. Pre-cleared lysates were then
incubated with specific antibodies (2.5 mg) overnight at 4uC.
Control immunoprecipitations without antibody (No Ab) and with
purified normal rabbit total IgGs (Santa Cruz) were also
performed. Immunocomplexes were recovered from lysates by
incubation at 4uC for 2 hours with 45 ml of protein A–Sepharose
pre-blocked with salmon sperm DNA (Upstate). Precipitates were
successively washed (10 min each wash) with 1.0 ml of the
following buffers: low salt (0.1% SDS, 1% Triton X-100, 2 mM
EDTA, 20 mM Tris-HCl pH 8.0 , 150 mM NaCl), high salt
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl
pH 8.0, 500 mM NaCl), LiCl (250 mM LiCl, 1% Nonidet P-40,
1% Na-deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8.0).
All wash buffers had protease inhibitors added. Following two final
washes in TE (10 mM Tris-HCl pH 8.0, 1 mM EDTA), the
immunocomplexes were finally eluted in 150 ml of TE/1% SDS
buffer (10 mM Tris-HCl pH 8.0, 5 mM EDTA, 1% SDS) by
incubation at 65uC for 15 min. The formaldehyde cross-link was
reversed by incubating the sample at 65uC overnight; the input
sample was processed in parallel with ChIP samples from this
point on. DNA fraction was recovered by proteinase K (Roche)
digestion followed by phenol-chloroform extraction and ethanol
precipitation in the presence of glycogen. DNA pellets were
resuspended in 200 ml of water. Real Time PCR reactions were
carried out in a final volume of 25 ml of iQ SYBR Green
Supermix (Bio-Rad), with 150 nM specific primers and 5 mlo f
DNA added. PCR amplification was performed on a iCyclerIQ
(Bio-Rad) thermal cycler adopting the following conditions: the
initial denaturation at 95uC for 10 min; 45 cycles of: 95uC for
30 sec, 60uC for 30 sec, and 72uC for 30 sec. The threshold cycle
(CT) values of ChIP signals detected by real-time PCR were
converted to the percentage of each ChIP signal for input DNA,
which were calculated by the delta–delta method according to the
following equation: sample signal=1006[2
(CT IP sample–CT Input)].
Antibodies used for immunoprecipitations were the following:
mouse monoclonal anti-poly(ADP-ribose) polymer (10 HA,
Trevigen); rabbit polyclonal anti-poly(ADP-ribose) polymerase 1
(Alexis); rabbit polyclonal anti-Ctcf (Upstate).
Primers used in real-time PCR assays were the following:
D1 sense 59-TATAGCCAGGAGGTGTGGGTG-39;
antisense 59AACGAGACCCCGGCTTTTT-39;
D2 sense 59-TCCTCTGCAAGAGCAGCACTA-39;
antisense 59- ATGTACCACACAGGGCAAGA-39;
D3 sense 59-TGTTTGTGCATGTGAGTGCA-39;
antisense 59-TCGGCACTTGAGAGCAGGTA-39;
D4 sense 59-TGAGTGCTGGAATCAAATGC-39;
antisense 59-AAGCCCCTGTAATTCCACTT-39;
D5 sense 59-AGAAGTGGTTCCTGGCCTTA-39;
antisense 59-TAACTCTATCCCCCTCCCCTT-39;
b-Actin sense 59-TTGGCTCCGCGTCGCTCACTCAC-39;
antisense 59-CCCCAGAATGCAGGCCTAGTAA-
CCGAGAC-39;
ICRM4 sense59-CAATGATTCATAAGGGTCAT-39;
antisense 59-CGTAAGTGCACAAATGCC-39.
DNA methyltransferase activity
Equal amounts of nuclear lysates were analyzed for DNA
methyltransferase activity by the EpiQuikTM DNA methyltrans-
ferase assay kit (Epigentek) following the manufacturer’s conditions.
Methyl-accepting ability assay
Methyl-accepting ability assay was carried out in a final volume
of 50 ml of 10 mM Tris-HCl pH 7.9, 10 mM MgCl2, 50 mM
NaCl, 1 mM dithiothreitol in the presence of 1 mg of purified
DNA and 1 unit of bacterial SssI methylase (New England
Biolabs), using as methyl donor 16 mM S-adenosylmethionine plus
10 mCi/ml of [methyl-3H] S-adenosylmethionine (GE Healthcare;
specific activity 70–80 Ci/mmol). The reaction mixture was
incubated for 1 hour at 37uC and the reaction was stopped at
60uC for 30 min after addition of 1% SDS and 250 mg/ml of
proteinase K. The incorporation of labeled methyl groups was
evaluated on purified DNA in a Beckman LS-6800 liquid
scintillation spectrometer.
Genomic bisulphite sequencing
Briefly, genomic DNA (1 mg) was denatured by adding NaOH
to a final concentration of 0.3 M for 15 minutes at 37uC. For the
sulphonation reaction, the sample was incubated in the dark for
17 hours at 55uC in the presence of 3.1 M sodium bisulphite,
0.5 mM hydroquinone and 6.25 M urea in a final volume of
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mixtures using the Wizard DNA Clean-Up system (Promega) and
resuspended in 50 ml of water. Alkaline desulphonation of DNA
was performed at 37uC for 15 min by the addition of NaOH to the
final concentration of 0.3 M. This solution was neutralized by
adding ammonium acetate (pH 7.0) to the a final concentration of
3.0 M. After ethanol precipitation, the modified DNA was
dissolved in 20 ml of water.
Genomic sequencing analysis of Dnmt1 promoter region
(Kimura et al. 2003) spanning from 2364 to 2103 (bp from the
first codon) was performed on bisulphite modified genomic DNA
(100 ng). The bisulphite modified promoter of Dnmt1 was
amplified using the following primers: 59- GGATTTTTTG-
GAAGTGGAATTATAG -39 sense and 59- CCACACAAAA-
CAAAAAAATAAAAAAA -39antisense. The amplified DNAs
were purified and cloned into the TOPO TA-cloning vector
(pCR 2.1-TOPO kit, Invitrogen). Twenty independent clones for
each sample were cultured in LB medium and the corresponding
recombinant plasmids were extracted (Fast Plasmid Extraction
Kit, Eppendorf). The purified plasmids were directly sequenced on
both strands by using a Rhodamina Terminator Cycle Sequencing
Ready Reaction Kit (Applied Biosystem) and an ABI PRISM 310
DNA Sequencer (Applied Biosystem), Primer pairs for sequencing
were M13 forward (220) and M13 reverse included in the kit.
Co-immunoprecipitation (Co-IP)
Nuclei obtained from L929 cells were lysed in IP buffer (50 mM
Tris-HCl pH 7.5, 5 mM EDTA, 300 mM NaCl, 1% Nonidet P-
40, 1% Triton X-100) supplemented with protease-inhibitors
(complete EDTA-free, Roche Applied Science). Lysates (1.5 mg)
were pre-cleared with protein A-(for IP anti PARP-1) or G (for IP
anti Dnmt1)-agarose beads (Upstate) on a rotative shaker at 4uC
for 2 h and 30 min. Pre-cleared lysates were incubated with
specific antibodies (mouse monoclonal Ab anti-Dnmt1, Imgenex;
and rabbit polyclonal Ab anti-PARP-1, Alexis) and with normal
rabbit or mouse IgG (Santa Cruz Biotechnology) on a rotative
shaker at 4uC. The agarose beads, previously saturated with
bovine serum albumin (1 mg/ml) overnight, were added to the
lysate/Ab solutions and incubated for 2 h on a rotative shaker at
4uC. Subsequently, beads were washed in IP buffer and boiled in
SDS-PAGE sample buffer, and the eluted proteins were analyzed
by western blotting.
siRNA treatment
siRNA treatment was performed to knockdown Ctcf expression
in L929 cells. SMART pool siRNAs (Dharmacon) specific for
murine Ctcf were transfected into 0.16610
6 cells in 35 mm culture
dishes using Lipofectamine 2000 (invitrogen). siGENOME non-
targeting siRNAs (Dharmacon) were transfected as a negative
control. After 48 hours from transfection cells were harvested and
processed for western blot analysis.
Methylation-sensitive southern blot analysis
DNA preparations (2 mg) were digested with 40 units of MspI or
HpaII (New England Biolabs) restriction enzymes for 16 hours at
37uC. After 1.5% agarose gel electrophoresis, the digested DNA
were blotted on Hybond-N nylon membrane (Amersham
Biosciences), and the presence of new HpaII cutting sites was
evidenced by hybridization to a 39-digoxigenin-labeled single
strand synthetic oligonucleotide as probe. Labeling of probe and
detection was performed using digoxigenin oligonucleotide 39-end
labeling kit and digoxigenin luminescent detection kit (Roche
Applied Science). Sequence of probe for minor satellite repeats
was: 59-GGAAACATGATAAAAACCACAGTGTAGAACATA-
TTAGATGAGTGAGTTACACTGAA AAACACATTCGTT-
GGAAACGGGATTTGTAGAACAGTGTATATCAATGAG-
TTACAATGAGAAACATC- 39 [49]. The oligo was made by
custom primers synthesis service (Invitrogen). As positive control
for DNA demethylation, digestion was performed in parallel on
DNA from 5-AZA treated cells.
Supporting Information
Materials and Methods S1 Supporting Material and Methods
Found at: doi:10.1371/journal.pone.0004717.s001 (0.03 MB
DOC)
Figure S1 Survival and cytotoxicity after PARG over-expres-
sion. A, Trypan blue exclusion test to determine the number of
surviving cells after transfection of pCS2-Myc-PARG at 24 and
72 hours of puromycin selection, as compared to control cells. B,
LDH assay to determine the relative cytotoxicity of transient
transfection at 24, 48 and 72 hours post transfection (p.t.) of pCS2-
Myc-PARG vs control cells. The value for the untreated samples
was set at 1.0. Untreated: non-transfected cell; mock: cells
transfected in absence of DNA. Data in A and B are reported as
mean6S.E. of three independent experiments.
Found at: doi:10.1371/journal.pone.0004717.s002 (7.74 MB TIF)
Figure S2 Analysis of cell cycle after PARG over-expression.
Cell cycle progression at 24 and 72 hours of puromycin selection
of cultures transfected with pCS2 or pCS2-Myc-PARG vectors
assayed by cytofluorimetric analysis.
Found at: doi:10.1371/journal.pone.0004717.s003 (1.57 MB TIF)
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